Brought to you by 
Bristol acquires fibrotic disease company Amira for $325mm up front
Jul 2011
Executive Summary
Marking its first foray into the fibrotic disease area, Bristol-Myers Squibb Co. is acquiring private Amira Pharmaceuticals Inc. (developing small molecules for disorders caused by inflammation) for $325mm up front and up to $150mm in earn-outs, in three increments of $50mm each. (One of the milestone payments is expected sometime this year.)
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Acquisition of Private Biotech
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol acquires fibrotic disease company Amira for $325mm up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice